American Journal of Obstetrics & Gynecology
Volume 186, Issue 5 , Pages 969-977 , May 2002

Hormone replacement therapy: Estrogen and progestin effects on plasma C-reactive protein concentrations

Received 19 April 2001 ,Revised 7 December 2001 ,Accepted 20 December 2001.

References 

  1. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–125
  2. Tracy RP. Epidemiological evidence for inflammation in cardiovascular disease. Thromb Haemost. 1999;82:826–831
  3. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36–44
  4. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation. 1994;90:775–778
  5. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al.  The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331:417–424
  6. Ferreiros ER, Boissonnet CP, Pizarro R, Merletti PF, Corrado G, Cagide A, et al.  Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation. 1999;100:1958–1963
  7. Haverkate F, Thompson S, Pyke S, Gallimore J, Pepys M. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349:462–466
  8. Kuller L, Tracy R, Shaten J, Meilahn E, for the MRFIT Research Group . Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol. 1996;144:537–547
  9. Tracy R, Kuller L, Psaty B, Cushman M, Meilahn E, Smith N. C-reactive protein and incidence of cardiovascular disease in older women: the Rural Health Promotion Project and the Cardiovascular Health Study [abstract]. Circulation. 1996;93:622
  10. Koenig W, Sund M, Frohlich M, Fischer H-G, Lowel H, Doring A, et al.  C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation. 1999;99:237–242
  11. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731–733
  12. Gram J, Bladbjerg E-M, Møller L, Sjøl A, Jespersen J. Tissue-type plasminogen activator and C-reactive protein in acute coronary heart disease: a nested case-control study. J Intern Med. 2000;247:205–212
  13. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985;313:1044–1049
  14. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol. 1990;97:1080–1086
  15. Grady D, Rubin SM, Petiti DB, Fox CS, Black D, Ettinger B, et al.  Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–1037
  16. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, et al.  The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med. 1994;154:1333–1339
  17. Nabulsi AA, Folsom AR, White A, Patsh W, Heiss G, Wu KK, et al.  Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women: the Atherosclerosis Risk in Communities Study. N Engl J Med. 1993;328:1069–1075
  18. Lee AJ, Lowe GDO, Smith WCS, Tunstall-Pedoe H. Plasma fibrinogen in women: relationships with oral contraception, the menopause and hormone replacement therapy. Br J Haematol. 1993;83:616–621
  19. Stefanick ML, Legault C, Tracy RP, Howard G, Kessler CM, Lucas DL, et al.  Distribution and correlates of plasma fibrinogen in middle-aged women: initial findings of the Postmenopausal Estrogen/Progestin Intervention (PEPI) Study. Arterioscler Thromb Vasc Biol. 1995;15:2085–2093
  20. Andersen LF, Gram J, Skouby SO, Jespersen J. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. Am J Obstet Gynecol. 1999;180:283–289
  21. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605–613
  22. Cushman M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arteriosler Thromb Vasc Biol. 1999;19:893–899
  23. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 1999;100:713–716
  24. van Baal WM, Kenemans P, van der Mooren MJ, Kessel H, Emeis JJ, Stehouwer CDA. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost. 1999;81:925–928
  25. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, et al.  Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/ Progestin Intervention (PEPI) Study. Circulation. 1999;100:717–722

☆ Reprint requests: Sven O. Skouby, Department of Obstetrics and Gynecology, Frederiksberg Hospital, DK 2000 Copenhagen, Denmark.

PII: S0002-9378(02)26602-8

doi: 10.1067/mob.2002.122414

American Journal of Obstetrics & Gynecology
Volume 186, Issue 5 , Pages 969-977 , May 2002

Article Tools

* Image Usage & Resolution